Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Specific targeting of HLA genes generates hypoimmunogenic hematopoietic stem cells for allogeneic transplantation

Yiwen Han, Zhaoyi Hou, Liang Shi et al. Nov 03, 2025 pp. 4089-4089 10.1182/blood-2025-4089

Abstract Pre-transplant human leukocyte antigen (HLA) matching between donors and recipients is essential for minimizing immunological rejec...

The association between sglt-2 inhibitor use and progression from monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans

Byron Sigel, Lawrence Liu, Mei Wang et al. Nov 03, 2025 pp. 4027-4027 10.1182/blood-2025-4027

Abstract Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are antidiabetic agents with known cardio- and renoprotective effec...

Microbiome and cytokine features are associated with graft-versus-host disease incidence in allogeneic hematopoietic cell transplantation patients

Antonio Luiz Cruz Gomes, Natalie Smith, Sally Mokhtari et al. Nov 03, 2025 pp. 6072-6072 10.1182/blood-2025-6072

Abstract Introduction The intestinal microbiota modulates the host immune-system and is particularly relevant in immune-...

Is 'severe’ imcd-IPL really severe?

Siyuan Li, Yu-han Gao, Yue Dang et al. Nov 03, 2025 pp. 1816-1816 10.1182/blood-2025-1816

Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder with heterogeneous clinical manifestations....

Targeting Epigenetic–Metabolic crosstalk in CML via butyrate-induced HDAC inhibition

Rita Vacca, Alice Danzero, Daniela Cilloni et al. Nov 03, 2025 pp. 6810-6810 10.1182/blood-2025-6810

Abstract Introduction Tyrosine kinase inhibitors (TKIs) have improved Chronic Myeloid Leukemia (CML) patient outcomes; however, a subset of p...

Efficacy and safety of the TEAM conditioning for autologous stem cell transplantation in lymphoma patients with high-risk of central nervous system relapse

Xi Qiu, Huawei Jiang, Zhaoxing Wu et al. Nov 03, 2025 pp. 5454-5454 10.1182/blood-2025-5454

Abstract Background: Despite advances in novel therapies, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantat...

Somatic mutations in cancer-related genes in chronic myeloid leukemia patients receiving asciminib

Elena Kuzmina, Ekaterina Chelysheva, Bella Biderman et al. Nov 03, 2025 pp. 2000-2000 10.1182/blood-2025-2000

Abstract Background: Identification of possible factors of resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)...

Liver disease in shwachman-diamond syndrome: A report from the shwachman-diamond syndrome registry

Jane Koo, Meghan Haney, Diana Schwarz et al. Nov 03, 2025 pp. 1436-1436 10.1182/blood-2025-1436

Abstract Background: Shwachman-Diamond Syndrome (SDS) is a ribosomopathy marked by marrow failure, exocrine pancreatic dysfunction, and leuk...

Physician-reported impact of vaso-occlusive crises in people with sickle cell disease: A multinational, real-world survey

Dionne Hines, Carmine Colavecchia, Emily Meier et al. Nov 03, 2025 pp. 6523-6523 10.1182/blood-2025-6523

Abstract Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a β-globin gene mutation producing sickle hemoglobin (H...

NSUN2/YBX1-mediated m5C modification enhances phgdh expression to drive immune evasion via PD-L1 and CCL2 axis in high-grade b-cell lymphoma

Guojun Zhang, Zhe Zhang Nov 03, 2025 pp. 5075-5075 10.1182/blood-2025-5075

Abstract High-grade B-cell lymphoma with double-hit (HGBL-DH), distinguished by simultaneous MYC and BCL-2 rearrangements, constitutes a not...

Car-T therapies show potential benefit as second-line treatment in relapsed/refractory large B-cell lymphoma: A bayesian meta-analysis of randomized controlled trials

Gowrishankar Palaniswamy, Ronit Bhuva, Hrishikesh Kommu et al. Nov 03, 2025 pp. 7239-7239 10.1182/blood-2025-7239

Abstract Introduction The advent of chimeric antigen receptor T-cell (CAR-T) therapies has transformed the management of relapsed/refractory...

Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis

Anushka Bhaskar, Anna Oh, William Shomali et al. Nov 03, 2025 pp. 6308-6308 10.1182/blood-2025-6308

Abstract Background: Chronic lymphocytic leukemia (CLL) is the most prevalent form of adult leukemia in the United States, accounting for 20...

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Samer Srour, Mehrdad Abedi, Amandeep Salhotra et al. Nov 03, 2025 pp. 932-932 10.1182/blood-2025-932

Abstract BACKGROUND Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only potentially curative option for several h...

Inhibition of Drp1, a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem-like properties in Acute Myeloid Leukemia

Priyanka Sharma, Saurabh Kumar Gupta, Anudishi Tyagi et al. Nov 03, 2025 pp. 5055-5055 10.1182/blood-2025-5055

Abstract Introduction: Mitochondrial fission is a critical aspect of mitochondrial dynamics, essential for maintaining mitochondrial functio...

Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor

Jean Lemoine, Ivan Cohen, Gabrielle Croston et al. Nov 03, 2025 pp. 2348-2348 10.1182/blood-2025-2348

Abstract Introduction: CD19-directed chimeric antigen receptor T-cell (CART19) immunotherapy has revolutionized the treatment of B-cell lymp...

Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with  Multiple myeloma: A multicentric experience

Gabriella Tomei, Sonia Morè, Francesca Di Landro et al. Nov 03, 2025 pp. 5777-5777 10.1182/blood-2025-5777

Abstract Multiple Myeloma (MM) is often diagnosed in patients (pts) aged > 75 years. These very elderly subjects are under-represente...

Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas

Michael Cook, Emeline Chong, Ava Clifford et al. Nov 03, 2025 pp. 5522-5522 10.1182/blood-2025-5522

Abstract Introduction: Bispecific CD20-directed/T cell-engaging antibodies (BsAbs) are FDA approved for treatment (tx) of patients (pts) wit...

From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS

Sven De Pourcq, Giorgio Mattiuz, Elena Tofacchi et al. Nov 03, 2025 pp. 3866-3866 10.1182/blood-2025-3866

Abstract Introduction Immune dysregulation is increasingly recognized as both a pathogenic driver and therapeutic target in Myelodysplastic S...

Low risk for meningococcal and other encapsulated bacteria infections with systemically administered pegcetacoplan in paroxysmal nocturnal hemoglobinuria and C3 glomerulopathies

Carlos de Castro, Viridiana Cano Garcia, Peter Hillmen Nov 03, 2025 pp. 6719-6719 10.1182/blood-2025-6719

Abstract Introduction: Complement inhibitors are promising therapies for complement-mediated conditions, including paroxysmal nocturnal hemo...

Final results of a phase I/II trial of palbociclib and CPX-351 in patients with Acute Myeloid Leukemia

Chana Peysin, Aziz Nazha, Wei Wei et al. Nov 03, 2025 pp. 3420-3420 10.1182/blood-2025-3420

Abstract Introduction Cytarabine resistance limits treatment efficacy in acute myeloid leukemia (AML), due in part to the asynchronous cell c...

Development of a high-affinity antibody specific to the predominant λ light chain amyloid subtype for AL amyloidosis immunotherapy

Michael Hughes, Gavreel Kalantarov, Jing Fu et al. Nov 03, 2025 pp. 576-576 10.1182/blood-2025-576

Abstract BACKGROUND Although current quadruplet anti-plasma cell treatments effectively eliminate the production of new amyloidogenic light...

Exploring the interplay of myeloma and acute decompensated heart failure: Mortality and comorbidity insights

Brett Cohen, Harsh Bhalala, Nicholas Roma et al. Nov 03, 2025 pp. 2199-2199 10.1182/blood-2025-2199

Abstract Background: Acute decompensated heart failure (ADHF) is a major driver of hospitalization and mortality, with outcomes potentially...

The point-of-care network with the BCMA-directed CART ARI0002h (Cesnicabtagene Autoleucel) in patients with relapsed/refractory multiple myeloma maintains efficacy and safety in real-world data

Aina Oliver-Caldés, Natalia Tovar, Valentin Cabañas et al. Nov 03, 2025 pp. 135-135 10.1182/blood-2025-135

Abstract Background: ARI0002h (cesnicabtagene autoleucel) is a BCMA-CART developed at Hospital Clinic de Barcelona (HCB). Approval was grant...

TP53 mutated clonal hematopoiesis patterns over serial follow up: A single center clinic experience

Tamanna Haque, Nicola Kim, Gabrielle Arauz et al. Nov 03, 2025 pp. 6706-6706 10.1182/blood-2025-6706

Abstract Background: Clonal hematopoiesis (CH) refers to acquired myeloid neoplasm (MN)-associated mutations that are detectable in blood by...

Characterization of disease presentation and clinical outcomes of chronic myelomonocytic leukemia and myelofibrosis with monocytosis

Patrick Crorkin, John Mascarenhas, Douglas Tremblay Nov 03, 2025 pp. 7348-7348 10.1182/blood-2025-7348

Abstract Introduction Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy defined by the presence of peripheral monocytosis a...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page